Dr.  Jens Hillengass (University of Heidelberg) is lead investigator for a Black Swan Research Initiative-supported study that assesses molecular disease heterogeneity in patients with multiple myeloma by imaging guided biopsy. In this video with IMF-TV, Dr. Hillengass explains the goals of this trial.